333 results on '"Lundberg, Pontus"'
Search Results
2. Mussel-Inspired Anchoring of Polymer Loops That Provide Superior Surface Lubrication and Antifouling Properties
3. Phase 3 randomized COMMODORE 2 trial : Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
4. Histamine-functionalized copolymer micelles as a drug delivery system in 2D and 3D models of breast cancer
5. A robust platform for functional microgels via thiol–ene chemistry with reactive polyether-based nanoparticles
6. Does the order of mutational acquisition in myeloproliferative neoplasms matter? Evidence from JAK2 exon 12 and DNMT3A co-mutant polycythemia vera
7. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
8. Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa.
9. Genetic Factors in Familial Manifestation of Primary Mediastinal Large B-Cell Lymphoma over Two Generations
10. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis
11. Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency
12. Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria : Long-term results from the phase I/II COMPOSER trial
13. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F–driven mouse model of MPNs
14. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
15. Results from the First Phase 3 Crovalimab (C5 Inhibitor) Study (COMMODORE 3): Efficacy and Safety in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
16. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model
17. A Gain-of-Function Mutation in EPO in Familial Erythrocytosis
18. Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor‐naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single‐arm study.
19. Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
20. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms
21. Erythropoietin receptor mutation—a rush of blood to the head?
22. Erythropoietin receptor mutation—a rush of blood to the head?
23. Detection of the germline KIT S476I mutation in a kindred with familial mastocytosis associated with gastrointestinal stromal tumors
24. Does the order of mutational acquisition in myeloproliferative neoplasms matter? Evidence from JAK2 exon 12 and DNMT3A co-mutant polycythemia vera
25. Case Report: Opposite Effects of BRAF Inhibition on Closely Related Clonal Myeloid Disorders
26. Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
27. Relevance of the N-terminal NLS-like sequence of the prion protein for membrane perturbation effects
28. MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages
29. Biomarker Analyses in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 Trial
30. Zinpentraxin Alfa Reduces Myelofibrosis in a JAK2-V617F Mouse Model of Myeloproliferative Neoplasms
31. Quantitative Analysis of Bone Marrow Features Highlights Heterogeneity in Myelofibrosis Patients Treated with Zinpentraxin Alfa in a Phase II Clinical Study
32. Uptake Mechanisms of Cell-Penetrating Peptides Derived from the Alzheimer’s Disease Associated Gamma-Secretase Complex
33. Prediction of Cell-Penetrating Peptides
34. N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis
35. JAK2 V617F-Mutated Myeloproliferative Neoplasia Developing Five Years after Wild-Type JAK2 Acute Myeloid Leukemia: A Case Report
36. Cell-Penetrating Short Interfering RNAs and Decoy Oligonucleotides
37. Two Novel Targeting Peptide Degrading Proteases, PrePs, in Mitochondria and Chloroplasts, so Similar and Still Different
38. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14
39. Induction of splice correction by cell-penetrating peptide nucleic acids
40. Moderne Leukämie-Diagnostik
41. Night Transplantation and Catecholamine Exposure Accelerates In Vivo Leukemia Development By Enhancing Bone Marrow Homing Capacity in Leukemic Cells
42. Optimization of Reverse Osmosis Performance
43. Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.
44. Människan påverkas av miljön
45. Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion
46. Catecholamine Exposure Accelerates In Vivo Leukemogenesis in Acute Myeloid Leukemia Patient Derived Xenografts
47. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14
48. RUNX1 Mutations Can Lead to Aberrant Expression of CD79a and PAX5 in Acute Myelogenous Leukemias: A Potential Diagnostic Pitfall
49. TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-κB mediated signaling in B-cells
50. A Gain-of-Function Mutation inEPOin Familial Erythrocytosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.